Monovalent blood brain barrier shuttle modules

A blood-brain barrier, monovalent technology, used in medical preparations with non-active ingredients, antibodies, targeting specific cell fusion, etc., can solve problems such as low antibody concentration and limited pharmacological effects

Inactive Publication Date: 2016-08-17
F HOFFMANN LA ROCHE & CO AG
View PDF86 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This would of course limit any pharmacological effect due to the low concentration of the antibody within the CNS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monovalent blood brain barrier shuttle modules
  • Monovalent blood brain barrier shuttle modules
  • Monovalent blood brain barrier shuttle modules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0156] Media and supplements for hCMEC / D3 (see WO 2006 / 056879 and Weksler, B.B. et al., FASEB J.19 (2005) 1872-1874) were obtained from Lonza. hCMEC / D3 cells (23-29 passage) on collagen-coated coverslips (microscope) or in flasks to confluency.

[0157] For all transcytosis assays, high-density wells (1×10 8 hole / cm 2 ) PET membrane filter inserts (0.4 μm pore size, 12 mm diameter) are / can be used in 12-well cell culture plates. For the apical and basolateral compartments, calculate the medium volume, which is 400 µL and 1600 µL, respectively. Use / can use rat tail collagen I (7.5μg / cm 2 ) followed by coating the apical chamber of the filter insert with fibronectin (5 μg / mL), with each incubation lasting 1 h at RT. For 10-12 days in EBM2 medium, grow hCMEC / D3 cells to a confluent monolayer (~2 × 10 5 cells / cm 2 ). Air filters were / can be blocked in PBS containing 1% BSA for 1 hour or overnight (o / n) before testing and then calibrated in EBM2 for at least 1 hour.

[015...

Embodiment 1

[0568] Immunization of rabbits and mice

[0569] Immunization of mice

[0570] By transdermal administration of 100 μg carrier DNA, followed by electroporation (2 square pulses of 1000V / cm, duration 0.1ms, interval 0.125s; followed by 4 square pulses of 287.5V / cm, duration 10ms, interval 0.125s), using a plasmid expression vector encoding full-length human or macaque TfR, genetically immunized NMRI mice. Mice received 6 or 7 consecutive immunizations on days 0, 14, 28, 42, 56, 70 and 84. The fourth and sixth immunizations were performed using a vector encoding macaque TfR; a vector encoding human TfR was used for all other immunizations. Blood was drawn on days 36, 78 and 92 and serum prepared for titration by ELISA (see below). Select the animal with the highest titer for a boost on day 96: 10 iv 6 Human TF-1 cells or 50 μg recombinant human soluble TfR lacking the helical domain (human TfR extracellular domain starting at Leu122 and ending at Asn608, expressed in HEK23...

Embodiment 2

[0576] B-cell clones from rabbits

[0577] Isolation of Rabbit Peripheral Blood Mononuclear Cells (PBMC)

[0578] In total, blood samples were obtained from 6 animals (2 wild type (wt) rabbits and 4 transgenic (tg) rabbits). These rabbits were derived from 2 different rounds of immunization: the first round of immunizations used 2 wt and 2 tg rabbits, while the second round of immunizations used 2 tg rabbits (see also example "Immunization of rabbits"). Whole blood containing EDTA was diluted two-fold with 1×PBS (PAA, Pasching, Austria), followed by lymphocyte separation medium (Cedarlane Laboratories, Burlington, Ontario, Canada) according to the manufacturer's instructions. Density centrifugation. PBMCs were washed twice with 1×PBS.

[0579] EL-4 B5 medium

[0580] Supplemented with 10% FCS (Hyclone, Logan, UT, USA), 2mM glutamine, 1% penicillin / streptomycin solution (PAA, Pasching, Austria), 2mM sodium pyruvate, 10mM HEPES (PAN Biotech, Aidenbach, Germany ) and 0.0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).

Description

field of invention [0001] The present invention relates to a blood-brain barrier shuttle module that has a binding specificity that specifically binds a blood-brain barrier receptor (BBBR) and is monovalent with respect to this binding specificity; also relates to the use of this construct as a blood-brain barrier Brain barrier shuttle bodies and methods for the treatment of neurological diseases. Background technique [0002] Brain penetration of neurological disease drugs, e.g., large biotherapeutics or small molecules with low brain penetration, is limited by the extensive impermeable blood-brain barrier (BBB) ​​and other cells in the neurovascular unit (NUV) Strict restrictions on components. A number of strategies to overcome this barrier have been tested, and one of them is the transcytosis pathway mediated by endogenous receptors (blood-brain barrier receptors) expressed on the brain capillary endothelium. Recombinant proteins, such as monoclonal antibodies or pepti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/18C07K16/28
CPCC07K16/18A61K2039/505C07K2317/31C07K2317/35C07K2319/33C07K16/2881A61P25/00A61P43/00A61K39/395A61K47/64A61K47/6849C07K2317/622C07K16/28C07K2317/55C07K2317/56
Inventor P·鲁格尔G·蒂芬塔勒E·默斯纳J·尼韦纳A·胡根马特尔邵翠英F·罗斯徐刚
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap